The influencing factors of Medical Tourism include promoting factors and hindering factors. Promoting factors for the development of Medical Tourism: One is the difference in medical expenses and the waiting time for treatment. This is the main factor that prompts many foreign patients to seek medical services in developing countries. For instance, Kittikanya's research found that...

The Europe Clinical Laboratory Tests Market, valued at USD 68.54 billion in 2024, is expected to grow at a CAGR of 2.21% during 2025–2034, reaching USD 85.21 billion by 2034. The market growth is fueled by the increasing adoption of molecular diagnostics, expansion of laboratory automation, and growing investment in healthcare infrastructure across Europe. The...

Rare Disease Drugs Market Overview The global Rare Disease Drugs Market size is expected to grow from USD 179.5 billion in 2025 to USD 364.1 billion by 2033, expanding at a CAGR of 9.6% during the forecast period. Rare diseases, defined by their low prevalence, often lack sufficient treatment options and are frequently overlooked in traditional drug development pipelines. However,...

"Regional Overview of Executive Summary Rett Syndrome Market by Size and Share The global Rett syndrome market size was valued at USD 35.34 billion in 2024 and is projected to reach USD 3,130.02 billion by 2032, with a CAGR of 75.15% during the forecast period of 2025 to 2032. Deliberately analyzed facts and figures of the market and keen business insights mentioned in Rett Syndrome...

The South Korea blastic plasmacytoid dendritic cell neoplasm (BPDCN) market, valued at USD 42.88 million in 2024, is forecast to expand at a compound annual growth rate (CAGR) of 7.20% between 2025 and 2034, reaching an estimated USD 85.78 million by 2034. Growth will be propelled by improved disease awareness, advancements in targeted therapies, wider diagnostic...

Ultomiris Drug Market: Driving Innovation in Rare Disease Treatment The global pharmaceutical landscape has been witnessing significant advancements in recent years, particularly in the treatment of rare and ultra-rare diseases. One such breakthrough therapy that has gained attention is Ultomiris (ravulizumab-cwvz), developed by Alexion Pharmaceuticals (now part of AstraZeneca). As...

Ultomiris Drug Market: Growth Opportunities, Trends, and Future Outlook The global pharmaceutical industry has been witnessing a surge in innovative treatments for rare diseases, with biologics and specialty drugs leading the transformation. Among them, Ultomiris (ravulizumab-cwvz), developed by Alexion Pharmaceuticals (now part of AstraZeneca), has emerged as a game-changing...